SAHPRA – review of certain products due to possible unacceptable carcinogen content.
If The International Regulatory Agencies have started investigating active ingredients that have common N-Nitrosamine impurities – which develop during the manufacturing process of these active ingredients (and which are above-authorized levels and are potential carcinogens). The active ingredients include azilsartan, candesartan, eprosartan, irbesartan, losartan, Olmesartan, telmisartan, valsartan, BUT also includes ranitidine.
Thus, SAHPRA – our local Regulatory Authority is reviewing all existing and all new applications that have been submitted to them to prevent products being registered with an active ingredient that does not conform to the required standard.
If vets are selling/ supplying compounded ranitidine products (as authorized to do as compounded products) they also need to recognise their responsibility in supplying a compounded product, and advising the client of any risks.
Whether this SAHPRA concern has the same implications for horses as for humans is currently unclear, but as professionals we need to be aware of this. Please see the link relating to this notice below: https://www.sahpra.org.za/wp-
Glynn Catton – SAEVA Medicine Committee
As COVID-19 continues to spread throughout most of the world, our thoughts and deepest sympathies are extended to all who have been affected by the disease. The AAEP has been monitoring the pandemic closely and is committed to helping your practice and your clients stay healthy. As health officials and our local communities continue to respond to the global spread of the virus, we are providing some resources for you.
In order to mitigate the risk of exposure to COVID-19 during interactions with clients, the AAEP Infectious Disease Committee shares the following advice for veterinary professionals Read more…
Applicants may submit any application for review through the new Covid19 submission platform – not only Covid 19 related products may be submitted.
The portal access is linked to your license number (for companies). There are one of three emails you can use to get more information and to request access to the portal – email@example.com, firstname.lastname@example.org or email@example.com. They will provide you with all the necessary guidance